Plain-English translation of NCT04231565 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is studying whether taking (TAF), an antiviral medication, can help people with chronic hepatitis B who have normal liver enzyme levels but still carry active virus in their blood. Currently, doctors don't usually treat patients in this situation, but research suggests that the virus can still damage the liver over time. This study will compare people who take the medication to people who don't, to see if treatment helps slow or prevent liver damage.
Many people with hepatitis B have normal liver enzyme levels but still carry the active virus, and doctors are uncertain whether to treat them. Recent studies suggest that even with normal enzymes, the virus can lead to serious liver problems like cirrhosis or liver cancer over time. This trial aims to find out if this medication can safely reduce the virus and prevent those complications.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to either take the medication once daily or to be in an observation group that does not receive treatment. You would continue in your assigned group for an extended period—potentially for years—and attend regular follow-up visits so researchers can monitor your liver health and virus levels. The medication has a good safety record with few side effects, but you'll need to commit to long-term follow-up appointments and blood tests to track how well the treatment is working.
AI-generated summary from trial data · Jul 14, 2026 · Not medical advice
China
Sponsor
Third Affiliated Hospital, Sun Yat-Sen University
Enrollment target
~200 participants
Started
June 2020
Primary completion
June 2024
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in March 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Qiumin Luo, Doctor
Third Affiliated Hospital, Sun Yat-Sen University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.